Coronavirus & The Deep State – UNITAID, Gilead Sciences & WuXi AppTech

| Last modified on June 29th, 2020 at 9:45 pm,

Read this report in: हिन्दी

This investigation by GreatGameIndia uncovers the Deep State collaborations between American and Chinese biotechs at the forefront of Coronavirus vaccine development – marketed worldwide by an entity funded by Bill Gates and Clinton initiative called UNITAID. WuXi AppTec’s partnership with Gilead Sciences in 2015 opens a window into the inner machinations of this global partnership and funding in the pharmaceutical industry amidst a worldwide pandemic.

Coronavirus & The Deep State - Unitaid, Gilead Sciences & WuXi AppTech
Coronavirus & The Deep State – Unitaid, Gilead Sciences & WuXi AppTech

WuXi AppTech & Gilead Sciences

Shanghai-based WuXi AppTec was formed out of the combination of Chinese WuXi PharmaTech and American AppTec Laboratory Services, which had centres in Minnesota, Pennsylvania and Georgia. On the other hand, Gilead Sciences is a vaccine manufacturer with a dark history of allegations of bioterrorism, including having Pentagon to bomb a competitors factory under the false pretext of association with Al-Qaeda.

In 2015, Gilead Sciences and WuXi AppTec announced a collaboration for a dedicated analytical and stability testing facility. “This strategic partnership further strengthens our close, broad-based collaboration with Gilead over many years,” said Ge Li, PhD, Founder and Chairman of WuXi AppTec. WuXi’s Lab Testing Division (LTD) would equip and operate an analytical testing facility with dedicated staff for Gilead Sciences.

R&D Centre in Wuhan

In 2012, WuXi AppTec opened an Research and Development centre in Wuhan, the very epicentre of the coronavirus crisis. Wuhan served as the strategic location to the firm’s network in central and western China. According to the history of the Shanghai and Hong Kong listed firm, it has since invested in another four American companies involved in laboratory services and R&D.

India in Cognitive Dissonance Book by GreatGameIndia
WuXi AppTech Wuhan facility
WuXi AppTech Wuhan facility

Even as coronavirus mandated a lockdown in Wuhan and forced WuXi AppTec to shutdown its facility there, the company was able to operate within its network in other cities in China and resume operations smoothly in middle of March.

Ties to the Government

Wuxi AppTec’s ties to the Chinese Government

It is almost certain that WuXi AppTec’s work was supervised by Chinese intelligence services – not only because of the high sensitivity of working in secure locations for virology research and testing, but also because of the company’s tight connections to the United States.

In any case, Wuxi AppTec is highly dependent on the heavy regulations in the Chinese biologics market. Under existing Chinese regulations, any new biologics must either be registered as an imported drug or be redeveloped and re-manufactured within the borders of China. If China would ever streamline, simplify or expedite its regulatory procedures, its clients’ demand for its services could decrease substantially, thus damaging its financial and operational health.

WuXi AppTec with members of local government in Shanghai, inaugurating a subsidiary in April, 2018
WuXi AppTec with members of local government in Shanghai, inaugurating a subsidiary in April, 2018

Wuxi AppTec, in its global offering in December, 2018, revealed that it had a RMB 480 million from the Shanghai Pudong Development Bank securitized by pledging shares of two its subsidiaries, which, however, is not state-owned (SPDB).

WuXi AppTec and its subsidiaries are also in frequent receipts of grants and subsidies from the Chinese government. For instance, it received RMB 106  million in Chinese government grants and subsidies in 2017 (p. 17 of 2018 annual report) and in the first half of 2019, it received an additional RMB 23.2 million in grants and subsidies.

Gilead Sciences ties to the American Government

Former U.S. Secretary of Defence, Donald Rumsfeld is the former Managing Director of Gilead Sciences. Although Gilead is a vaccine manufacturer, Donald Rumsfeld’s profiteering with Gilead extends into the area of warfare as well. In 1997, he initiated research on bioterrorism with work on a molecule called Cidofovir, which was traditionally used in the treatment of smallpox. In 1998, Donald Rumsfeld convinced Bill Clinton to bomb a factory of Al-Shifa, a rival and competitor of Gilead in Sudan, under the pretext that the Company was manufacturing chemical weapons for Al-Qaeda.

Donald Rumsfeld Gilead Sciences
Donald Rumsfeld former Chairman of Gilead Sciences

The interesting part is, Gilead was part of the vaccine lobby at whose behest the WHO faked the H1N1 pandemic in 2009, and kept it a secret from people until committees were setup which exposed the entire racket.

The role of Clinton in Gilead Sciences is much deeper than is alluded above. Clinton initiative has helped fund a global pharma cartel pushing the drug developed by associated biotechs onto sovereign nations (this will be discussed later in the report).

Coronavirus Vaccine Development

In January, 2020, WuXi AppTec announced an accelerated development of multiple neutralizing antibodies for the outbreak of COVID-19 in Wuhan. It said that the antibodies under development, which are from certain global biotech companies, are “potent in neutralizing COVID-19 in preliminary studies.”

Similarly, egged on from investment by certain “unidentified global vaccine leader,” WuXi AppTec’ spun off company WuXi Biologics is exclusively manufacturing one of the company’s vaccine products in a joint venture with Shanghai Hile Biotechnology. We assume the unnamed and unidentified global vaccine leader to be none other than Gilead Sciences.

It is highly likely that WuXi AppTec would have helped Gilead Sciences in the development of Remdesivir. Given WuXi’s presence in Wuhan and its range of service offerings, from small molecule therapeutics and testing to medical device testing, it is highly probable that it played an active part in the testing of Gilead’s Remdesivir. Indeed, WuXi’s Lab Testing Division (LTD), described as  the “complete package for clinical trials,” was explicitly part of the 2015 partnership between Gilead Sciences and WuXi AppTec.

Gilead’s Remdesivir

Gilead’s drug Remdesivir is being actively promoted by the World Health Organization (WHO) as a coronavirus remedy, despite experts having raised concerns over the alleged ineffectiveness of the drug.

Doctors Without Borders along with over 150 organisations and individuals said it was “Unacceptable for Gilead’s Remdesivir to be put under the Company’s exclusive control,” news agency AFP reported.

WuXi Biologics & Vir Biotechnology

Meanwhile, WuXi Biologics has partnered with Vir Biotechnology to develop and manufacture therapies to combat COVID-19. The collaboration will advance and produce human monoclonal antibodies (mAbs), with WuXi conducting the cell-line research, process and formulation development and initial manufacture of Vir’s antibodies for clinical progress. If the coronavirus treatment obtains regulatory approval in China, WuXi will commercialize the product in China and Vir in other markets globally.

Interestingly, the CEO of Vir, George Scangos earlier served as President of Bayer Biotechnology and was a Professor of Biology at Johns Hopkins University – which interestingly came up with the COVID-19 Tracker Dashboard. Johns Hopkins University is already partnering with UNITAID for various projects.

UNITAID – The Pharma Cartel

We can see the germination of cartelization in the global pharmaceutical industry in the form of United nations backed group – UNITAID. It works with the help of partners such as the Clinton Health Access Initiative and donors such as the Bill & Melinda Gates Foundation to “give technical assistance and to implement grants in the field.”

Such grants into medicine and healthcare sector by Bill Gates have wreaked havoc on nations which was most recently exposed on the world stage by none other than Robert F. Kennedy Jr., the nephew of former American President John F. Kennedy. And India is their testing field. Even the much sought after COVID-19 drug hydroxychloroquine was tested by East India Company on Indian soil. Already WHO has initiated a COVID-19 Surveillance Project in India in partnership with the Ministry of Health and Family Welfare. The data gathered through full-scale surveillance will be used to make future Indian nation policies.

As of 2019, UNITAID’s total grants stood at $1.3 billion. Its practical mandate is to create a “patent pool” for pharmaceutical companies in order to produce generic drugs for distribution to low and middle income nations, thus sharing a large income stream from various patents with select few Companies and donors.

UNITAID Pharma Cartel
UNITAID – The Pharma Cartel

Gilead Sciences was at the time, seen as the progenitor of the patent pool concept c. 2010. UNITAID was enthusiastically promoted by none other than billionaire George Soros. Although his latest quarterly investment declarations do not show a holding in WuXi AppTec nor in Gilead Sciences, George Soros’ is known to have invested in both the companies in the not-so-distant past.

This is also coincidently, right around the time the patent pool concept at UNITAID would have come in to play, enabling billionaires and multinational cartels to cash in on an outbreak of any disease worldwide. In the low and middle income countries, the huge numbers of population would necessitate orders in large numbers, while in the rich countries, patent protection would guarantee high prices and enormous monetization. Meanwhile, this Deep State global pharma cartel is actively engaged in pushing the drug developed by associated biotechs onto sovereign nations.

For latest updates on the outbreak check out our Coronavirus Coverage.

Send in your tips and submissions by filling out this form or write to us directly at the email provided. Join us on WhatsApp for more intel and updates.

GreatGameIndia is a journal on Geopolitics and International Relations. Get to know the Geopolitical threats India is facing in our exclusive book India in Cognitive Dissonance. Past magazine issues can be accessed from the Archives section.

We need your support to carry on our independent and investigative research based journalism on the external and internal threats facing India. Your contribution however small helps us keep afloat. Kindly consider donating to GreatGameIndia.